Share the Video:

A conversation with Amanda Feilding and Rick Doblin, Ph.D.

PS2023DMTLSDMDMAPsilocybinPsychedelic ScienceResearch
Amanda Feilding is the Founder and Executive Director of the Beckley Foundation, and is widely recognised as a leading force behind the current Psychedelic Renaissance. By establishing key Research Programmes at some of the world’s most prestigious institutions (including Imperial College London, UCL, Maastricht University), she has propelled the field forward over the last 24 years, conducting landmark studies, such as the world’s first psilocybin for treatment-resistant depression study, the world’s first LSD, MDMA and DMT brain imaging studies, plus the initiation and collaboration with Johns Hopkins on the first study using psilocybin-assisted psychotherapy to overcome nicotine addiction. She has also co-authored over 80 research papers.

Become a MAPS Member with a monthly donation

As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.

Related Videos

PS2023DMTMDMAPsilocybinPsychedelic ScienceResearchResearch and Science

(S1.2) Alexander Shulgin Research Institute: Chemistry for Consciousness

Dr. Alexander Shulgin was a prolific psychedelic researcher, known as the "Godfather of Psychedelics". Drs. Paul Daley and Nicholas Cozzi now lead the Alexander Shulgin Research Institute in creating new,

PS2023KetamineMDMAPsilocybinPsychedelic Assisted TherapyPsychedelic ScienceResearch

Psychedelics as The Great Disrupters: Reconstructing the Future of Mental Healthcare

Dr. Ben Sessa will discuss similarities among MDMA, ketamine, and psilocybin in clinical settings, exploring their potential in treating trauma-based disorders and challenges in psychedelic medicalization.

Ben Sessa

PS20235-MeO-DMTAyahuascaLSDPsilocybinPsychedelic ScienceResearch

Exploring the Use of Human Brain Organoids to Study Psychedelics

Brain organoids, resembling miniature brains, are grown from iPS cells for studying brain formation, diseases, and drug effects. Recent research explores psychedelics' therapeutic potential and mechanisms on brain organoids.

Stevens Rehen

PS2023BusinessHealth ConditionsMicrodosingPsilocybinPsychedelic ScienceResearch

Psilocybin Mushrooms and their Tryptamines: Potential Medicines for Neurogeneration

Paul discusses the historical use and potential for neurological health of psilocybin mushrooms, based on his team's molecular research and clinical studies at MycoMedica Life Sciences.

PS2023MDMAPolicy and AdvocacyPsychedelic Assisted TherapyPsychedelic ScienceResearchResearch and Science

Priorities for the next generation of psychedelic science

NIMH Director Joshua A. Gordon and trauma researcher Barbara O. Rothbaum discuss the current state and future directions of psychedelic research, emphasizing the need for deeper understanding and robust study

Joshua A Gordon

PS2023MDMAPsychedelic Assisted TherapyPsychedelic ScienceResearch

Grounding Psychedelic Research in Memory for Advancing Psychedelic Drug Discovery

M.K.D. discusses how psychedelics impact memory formation, suggesting potential for harnessing plasticity. J.K. concludes on how understanding mnemonic effects can shape clinical use and drug design.

James Keim

PS2023Health ConditionsPsilocybinPsychedelic Assisted TherapyPsychedelic ScienceResearchTherapy Ethics

Family Matters in Psychedelic Therapy: Lessons Learned from a Psilocybin Trial for Anorexia Nervosa

Family involvement in psychedelic therapy can optimize outcomes and prevent problematic patterns. Ethical, neurobiological, and psychological aspects, along with clinical trial data, support the benefits of engaging family members.

Jennifer Danby

PS2023MDMAPolicy and AdvocacyPsychedelic Assisted TherapyPsychedelic SciencePublic BenefitResearch

Preview Scene from Prescription X: The Rick Doblin and MAPS Documentary (Work in Progress)

"Prescription X: The Rick Doblin Story" documents Dr. Rick Doblin's quest with MAPS to legalize MDMA and psychedelics for therapy, culminating in a revealing film by Nirvan and Dream Mullick.

Nirvan Mullick, Dream Mullick

PS2023Ancestral KnowledgeIndigenous PeoplePlant MedicinePsilocybinPsychedelic ScienceResearch

History and archeology of psilocybin mushrooms in Mesoamerica

Research on psilocybin mushroom use in Mesoamerica explores archeological evidence from Maya, Mixtecs, and Aztecs through various sources, aiming to encourage interpretations based on scientific evidence and a humanistic approach.

Osiris Sinuhé González Romero